Pelareorep Earns FDA Fast Track Designation in Second-Line Anal Cancer

The FDA has granted fast track designation to pelareorep in combination with a checkpoint inhibitor for the treatment of patients with inoperable, locally recurrent, or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on or were intolerant to at least 1 prior line of systemic therapy, according to a news release from the developer, Oncolytics Biotech.¹

What data support the fast track designation in anal cancer?

The designation is supported by efficacy data from the phase 1/2 GOBLET trial (NCT07280377), which evaluated pelareorep in combination with a checkpoint inhibitor in patients with advanced SCAC whose disease progressed following prior therapy. Previously reported results, as of October 2025, showed an objective response rate (ORR) of 30% (n = 6/20 patients). Durable complete responses were observed 2 patients, 1 patient had an ongoing response beyond 2 years, 1 patient had a sustained response for 15 months, and 1 patient had an ongoing response at 64 weeks; the median duration of response (DOR) was 15.5 months. Additionally, the 12-month overall survival (OS) rate was 82%.¹

The designation follows an April 2026 meeting between the developers and the FDA regarding a potential registrational development strategy for pelareorep in this setting, which the company said provided a clear regulatory framework to advance toward a pivotal study.

“This fast track designation represents another important regulatory milestone for Oncolytics and reflects the significant progress we have made over the past twelve months in advancing pelareorep toward potential registration,” stated Jared Kelly, chief executive officer of Oncolytics, in the press release.¹ “Our April meeting with the FDA provided important clarity regarding a potential registrational pathway for pelareorep in second-line and later anal cancer, reinforcing our confidence in the program and our strategy to address an area of significant unmet need.”

How was the GOBLET trial designed?

In cohort 4 of the GOBLET trial, pelareorep was evaluated in combination with atezolizumab (Tecentriq) in patients with metastatic unresectable anal cancer.⁴ Eligible patients had an ECOG performance status of 1 or lower, measurable disease per RECIST v1.1, and adequate hematological, renal, and hepatic function. Patients were excluded if they had a life expectancy of less than 3 months or prior HIV infection if the CD4–positive T cell count was less than 300 cells/µl.

Pelareorep was administered at 5.4 x 10¹⁰ median tissue culture infectious dose 50 via a 1-hour intravenous infusion, and atezolizumab was given at 840 mg via intravenous infusion.

The primary end point of the trial was ORR in cohorts 1, 2, 3, and 4; the secondary end points were PFS, DOR, disease control rate, and OS.

What is pelareorep's regulatory history in gastrointestinal cancers?

This is the third fast track designation the FDA has granted to pelareorep in gastrointestinal cancers, following designations in KRAS-mutated metastatic colorectal cancer (CRC) in February 2026 and pancreatic cancer in late 2022. Previous coverage of the CRC designation, which was supported by data from the phase 1 REO 022 trial (NCT01274624), showed an ORR of 33%, a median PFS of 16.6 months, and a median OS of 27.0 months with the pelareorep-based therapy.³

What is pelareorep and how does it work?

Pelareorep is an intravenously delivered, systemically active investigational immunotherapy that selectively replicates within tumor cells while activating innate and adaptive anti-tumor immune responses. The agent upregulates inflammatory cytokines that promote the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, converting immunologically cold tumors into hot tumors that are more responsive to immune-based therapy.

References

1. Oncolytics Biotech® receives fast track designation for pelareorep in second-line and later anal cancer. News release. Oncolytics Biotech Inc. July 20, 2026. Accessed July 22, 2026. https://tinyurl.com/2v6v8zdu
2. Oncolytics Biotech reports updated anal cancer data showing objective response rate more than double the current standard of care. News release. Oncolytics Biotech Inc. October 28, 2025. Accessed July 22, 2026. https://tinyurl.com/2bfsr99x
3. Oncolytics Biotech® receives FDA fast track designation for pelareorep in 2L KRAS-mutant MSS metastatic colorectal cancer. News release. Oncolytics Biotech Inc. February 4, 2026. Accessed July 22, 2026. https://tinyurl.com/7br4n9m5
4. A study in advanced or metastatic gastrointestinal cancers exploring treatment combinations with pelareorep and atezolizumab (GOBLET). ClinicalTrials.gov. Updated December 12, 2025. Accessed July 22, 2026. https://tinyurl.com/mpspf54e